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1. INTRODUCTION {#cas14117-sec-0001}
===============

Gastric cancer is the 3rd leading cause of cancer‐related deaths worldwide.[1](#cas14117-bib-0001){ref-type="ref"} Fluoropyrimidines have been used as key drugs for patients with metastatic gastric cancer for more than half a century. It is known that female patients treated with fluoropyrimidines develop leukopenia, stomatitis, diarrhea, nausea, vomiting, and alopecia more often and more severely than male patients.[2](#cas14117-bib-0002){ref-type="ref"}, [3](#cas14117-bib-0003){ref-type="ref"}, [4](#cas14117-bib-0004){ref-type="ref"}, [5](#cas14117-bib-0005){ref-type="ref"}, [6](#cas14117-bib-0006){ref-type="ref"} Dose modification and the administration schedule of 5‐fluorouracil (5‐FU), a fluoropyrimidine, and optimum supportive therapies for female patients are not under current consideration and are not implemented in clinical practice, even though sex‐related differences in adverse reactions to fluoropyrimidines have been previously reported. Lower clearance of 5‐FU, could reduce the activity of dihydropyrimidine dehydrogenase (DPD), which is the initial enzyme in catabolism of 5‐FU.[2](#cas14117-bib-0002){ref-type="ref"}, [7](#cas14117-bib-0007){ref-type="ref"} Polymorphisms in DPD or thymidylate synthase[5](#cas14117-bib-0005){ref-type="ref"}, [8](#cas14117-bib-0008){ref-type="ref"} are thought to be possible causes of sex‐related differences in adverse events following fluoropyrimidine treatment, although the fundamental cause of this perceived difference is not yet known. Furthermore, a previous investigation into DPD expression and activity in the human liver did not reveal any sex‐related differences.[5](#cas14117-bib-0005){ref-type="ref"}

Sex‐related differences in the toxicity of anticancer agents have not only been observed for 5‐FU treatment, but also for cisplatin and adriamycin, and in other anticancer agents.[9](#cas14117-bib-0009){ref-type="ref"} Female patients had significantly higher rates of vomiting and nausea, however the cause of this sex‐related difference is also unknown.[10](#cas14117-bib-0010){ref-type="ref"} Conversely, body mass index was inversely correlated with a decrease in platelet count following cisplatin and etoposide treatment, whereas there was no significant effect of sex on this related parameter.[11](#cas14117-bib-0011){ref-type="ref"}

S‐1 is an oral combination preparation consisting of tegafur, a prodrug of 5‐FU, and the modulators gimeracil and oteracil potassium. Gimeracil prevents the degradation of 5‐FU by reversibly inhibiting DPD which is the primary metabolizing enzyme of fluorouracil, and oteracil potassium inhibits the activity of 5‐FU in the gastrointestinal tissue and decreases gastrointestinal toxicity.[12](#cas14117-bib-0012){ref-type="ref"} In patients with compromised renal function, gimeracil clearance is decreased, leading to high concentrations of 5‐FU in the blood and an increased risk of 5‐FU‐related side effects.[13](#cas14117-bib-0013){ref-type="ref"} We examined the incidence of diarrhea in metastatic colorectal cancer patients treated with S‐1 plus oxaliplatin (SOX) and plus bevacizumab, according to renal function in the previous SOFT trial.[14](#cas14117-bib-0014){ref-type="ref"} The incidence of grade 3, or higher, diarrhea among patients with a creatinine clearance rate (CCr) of \<70 mL/min before treatment exceeded 20% and tended to be higher than the incidence among patients with a CCr of ≥70 mL/min. Another study, G‐SOX, compared treatment with SOX and treatment with S‐1 plus cisplatin (CS) and demonstrated comparable results for both treatments in progression‐free survival (PFS) and overall survival (OS).[15](#cas14117-bib-0015){ref-type="ref"} In this study, we aimed to evaluate and compare the safety and efficacy of the SOX and CS therapies in female and male patients with metastatic gastric cancer.

2. MATERIALS AND METHODS {#cas14117-sec-0002}
========================

2.1. Patients {#cas14117-sec-0003}
-------------

The G‐SOX trial was a randomized, open‐label, phase III study that compared the efficacy and safety of the SOX and CS treatment regimens in patients with curatively unresectable, advanced, or recurrent gastric cancer.[15](#cas14117-bib-0015){ref-type="ref"} In total, 685 randomized patients were studied and data collected from January 2010 until October 2011. The SOX regimen was confirmed to be non‐inferior to the CS regimen. In the SOX regimen, S‐1 was given orally for the 1st 2 wk of a 3‐wk cycle, and oxaliplatin was infused at 100 mg/m^2^ on day 1. In the CS regimen, S‐1 was given for the 1st 3 wk of a 5‐wk cycle, and cisplatin was administered at 60 mg/m^2^ on day 8. The CCr was estimated using the Cockcroft‐Gault equation. The proportion of female patients treated with SOX and CS was 24.0% (81/338) and 27.5% (92/335) in the safety analysis set (SAF), and 24.3% (81/333) and 27.3% (90/330) in the full analysis set (FAS), respectively.

2.2. Statistical analysis {#cas14117-sec-0004}
-------------------------

Median OS and PFS were estimated using the Kaplan‐Meier method. Differences in therapeutic efficacy between SOX and CS were tested using the log‐rank test. Statistical significance was considered to be at a value of *P *\<* *.05. The Cox proportional hazards model was used to estimate hazard ratios (HRs) of SOX compared with CS with 95% confidence intervals (CIs). Efficacy was analyzed in the FAS, which included patients who met the main inclusion criteria and none of the exclusion criteria in the SAF.

The incidence of adverse events in female or male patients during the 1st treatment cycle was compared between the two regimens using Fisher\'s exact test and logistic regression. Multivariate analyses for toxicities were also carried out using a logistic regression model. Adverse events were assessed in accordance with the Common Terminology Criteria for Adverse Events version 3.0. Furthermore, treatment delivery was evaluated for both women and men in both treatment groups. Statistical analyses were performed using SAS version 9.3 software (SAS Institute).

3. RESULTS {#cas14117-sec-0005}
==========

Baseline characteristics of all patients enrolled in the G‐SOX study were comparable between the two sexes and treatment groups. The numbers of histologically undifferentiated type gastric cancer were higher in women than in men (Table [1](#cas14117-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics in male and female patients

                                                            SOX          CS                                             
  --------------------------------------------------------- ----- ------ ---- ------ ------ ------ ------ ------ ------ ------
  Age                                                                                                                   
   \<65                                                     111   43.2   42   51.9   .201   109    44.9   53     57.6   .038
   ≥65                                                      146   56.8   39   48.1   134    55.1   39     42.4          
  ECOG performance status                                                                                               
   0                                                        183   71.2   56   63.5   .414   177    72.8   59     64.1   .109
   1                                                        72    28.0   23   28.4   62     25.5   33     35.9          
   2                                                        2     0.8    2    2.5    4      1.6    0      0             
  Unresectable                                              207   80.5   71   87.7   .182   199    81.9   78     84.8   .628
  Recurrent                                                 50    19.5   10   12.3          44     18.1   14     15.2   
   Adjuvant chemotherapy (+)                                24    9.3    7    8.6           20     8.2    9      9.8    
   Adjuvant chemotherapy (‐)                                26    10.1   3    3.7           24     9.9    5      5.4    
  Tumor histology                                                                                                       
   Differentiated type                                      125   48.6   29   35.8   .055   119    49.0   29     31.5   .005
   Undifferentiated type                                    132   51.4   52   64.2   124    51.0   63     68.5          
  Primary tumor                                                                                                         
   ‐                                                        66    25.7   13   16.0   .097   62     25.5   17     18.5   .196
   +                                                        191   74.3   68   84.0   181    74.5   75     81.5          
  No. of metastatic sites                                                                                               
   1                                                        87    33.9   22   27.2   .377   78     32.1   26     28.3   .455
   2                                                        105   40.9   33   40.7   107    44.0   36     39.1          
   ≥3                                                       59    23.0   24   29.6   57     23.5   27     29.3          
  Metastatic site [b](#cas14117-note-0003){ref-type="fn"}                                                               
   Liver                                                    104   40.5   22   27.2          101    41.6   30     32.6   
   Lung                                                     32    12.5   5    6.2           27     11.1   8      8.7    
   Lymph node                                               225   87.5   74   91.4          214    88.1   79     85.9   
   Peritoneum                                               45    17.5   21   25.9          44     18.1   21     22.8   

Abbreviations: CS, cisplatin plus S‐1; ECOG, Eastern Cooperative Oncology Group; SOX, S‐1 plus oxaliplatin.

^a^Fisher\'s exact test; comparing proportion of each characteristic.

^b^Patients can be included in more than one category.
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3.1. Safety {#cas14117-sec-0006}
-----------

Adverse events are listed in Table [2](#cas14117-tbl-0002){ref-type="table"}. The median CCrs of female patients in the SOX group and the CS group were 72.9 mL/min (range, 36.5‐137.7 mL/min) and 76.8 mL/min (41.7‐211.0 mL/min), and those of male patients were 75.8 mL/min (33.7‐189.2 mL/min) and 79.4 mL/min (41.1‐151.2 mL/min), respectively. Female patients treated with SOX developed leukopenia, neutropenia, nausea, and vomiting significantly more frequently than male patients, while women treated with CS demonstrated vomiting and stomatitis in the 1st treatment cycle more often, regardless of renal function, as compared with men. In contrast, male patients undergoing CS therapy experienced thrombocytopenia in the 1st cycle more often compared with female patients. Sex was an independent predictive marker of those toxicities (Table [3](#cas14117-tbl-0003){ref-type="table"}). Thrombocytopenia following CS treatment was also observed more frequently in patients aged 70 years or older as measured by multivariate analysis.

###### 

Adverse events during the first cycle of treatment with S‐1 plus oxaliplatin or S‐1 plus cisplatin by creatinine clearance

                      SOX                   CS                                                                                  
  ------------------- ----- ---- ----- ---- -------- ---------------- -------- ---- ---- ----- ---- --------- ----------------- --------
  Leukopenia          33    41   68    27   .018     1.9, 1.1‐3.2     .015     46   50   121   50   1.0       1.0, 0.62‐1.6     .97
   CCr 70 mL/min \>   16    46   29    30   .098     2.0, 0.91‐4.4    .086     23   64   50    60   0.84      1.2, 0.52‐2.6     .71
   70 mL/min≤         17    37   38    24   .092     1.9, 0.92‐3.7    .085     23   42   71    45   0.75      0.88, 0.47‐1.6    .69
  Neutropenia         42    52   84    33   .0024    2.2, 1.3‐3.7     .002     49   53   150   62   0.17      0.71, 0.44‐1.1    .16
   CCr 70 mL/min\>    22    63   36    37   .0098    2.9, 1.3‐6.5     .009     25   69   58    70   1.0       0.98, 0.42‐2.3    .96
   70 mL/min≤         20    44   48    30   .11      1.8, 0.90‐3.5    .099     24   44   91    58   0.085     0.57, 0.31‐1.1    .075
  Thrombocytopenia    16    20   66    26   .30      0.71, 0.39‐1.3   .28      31   34   121   50   0.0097    0.51, 0.31‐0.85   .009
   CCr 70 mL/min\>    5     14   26    27   .17      0.46, 0.16‐1.3   .15      17   47   46    55   0.43      0.72, 0.33‐1.6    .41
   70 mL/min≤         11    24   39    25   1.0      0.96, 0.45‐2.1   .92      14   26   75    48   0.0044    0.38, 0.19‐0.75   .005
  Nausea              46    57   103   40   .010     2.0, 1.2‐3.3     .009     55   60   123   51   0.14      1.5, 0.89‐2.4     .13
   CCr 70 mL/min\>    21    60   41    42   .077     2.1, 0.95‐4.6    .067     23   64   44    53   0.32      1.6, 0.70‐3.5     .27
   70 mL/min≤         25    54   61    39   .064     1.9, 0.98‐3.7    .059     32   58   78    49   0.28      1.4, 0.77‐2.7     .26
  Vomiting            30    37   45    18   \<.001   2.8, 1.6‐4.8     \<.001   38   41   48    20   \<0.001   2.9, 1.7‐4.8      \<.001
   CCr 70 mL/min\>    13    37   22    22   .12      2.0, 0.89‐4.7    .093     20   56   21    25   0.0029    3.7, 1.6‐8.4      .002
   70 mL/min≤         17    37   23    15   .0014    3.4, 1.6‐7.2     .001     18   33   27    17   0.021     2.4, 1.2‐4.7      .016
  Diarrhea            30    37   76    30   .22      1.4, 0.83‐2.4    .21      37   40   78    32   0.20      1.4, 0.87‐2.3     .16
   CCr 70 mL/min\>    13    37   37    38   1.0      0.97, 0.44‐2.2   .95      17   47   29    35   0.22      1.7, 0.75‐3.7     .21
   70 mL/min≤         17    37   39    25   .13      1.8, 0.89‐3.6    .10      20   36   48    30   0.41      1.3, 0.69‐2.5     .41
  Stomatitis          6     7    24    9    .82      0.78, 0.31‐2.0   .60      29   32   50    21   0.043     1.8, 1.0‐3.0      .036
   CCr 70 mL/min\>    3     9    13    13   .56      0.61, 0.16‐2.3   .47      10   28   23    28   1.0       1.0, 0.42‐2.4     .99
   70 mL/min≤         3     7    11    7    1.0      0.93, 0.25‐3.5   .92      19   35   26    17   0.0070    2.7, 1.3‐5.4      .006

Abbreviations: 95%CI, 95% confidence interval; CCr, creatinine clearance rate; CS, cisplatin plus S‐1; OR, odds ratio; SOX, S‐1 plus oxaliplatin.

^a^ Fisher\'s exact test; comparing frequency of adverse events.
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###### 

Multivariate analyses for adverse events during the first cycle of treatment with S‐1 plus oxaliplatin and S‐1 plus cisplatin

                                           Leukopenia        Neutropenia       Thrombocytopenia   Nausea           Vomiting          Diarrhea         Stomatitis
  ---------------------------------------- ----------------- ----------------- ------------------ ---------------- ----------------- ---------------- ----------------
  S‐1 plus oxaliplatin                                                                                                                                
   Sex, female vs male                                                                                                                                
   OR, 95%CI                               1.9, 1.1‐3.3      2.2, 1.3‐3.7      0.70, 0.39‐1.32    2.0, 1.2‐3.3     2.8, 1.6‐4.9      1.3, 0.78‐2.3    0.73, 0.28‐1.9
   *P* value                               .015              .0036             .25                .0096            .0004             .30              .51
   CCr, 70 mL/min ≤ vs 70 mL/min \>                                                                                                                   
   OR, 95%CI                               0.78, 0.43‐1.4    0.55, 0.31‐0.97   0.82, 0.43‐1.5     0.94, 0.55‐1.6   0.68, 0.35‐1.3    0.56, 0.32‐1.0   0.52, 0.20‐1.3
   *P* value                               .41               .039              .53                .83              .25               .053             .17
   BMI, median ≤ vs median \> per gender                                                                                                              
   OR, 95%CI                               0.72, 0.43‐1.2    0.81, 0.50‐1.3    1.2, 0.67‐2.0      0.76, 0.48‐1.2   0.85, 0.48‐1.5    1.3, 0.78‐2.1    1.2, 0.55‐2.8
   *P* value                               .20               .40               .61                .26              .59               .33              .60
   Age, 70 ≤ vs 70 \>                                                                                                                                 
   OR, 95%CI                               0.91, 0.50‐1.6    0.63, 0.36‐1.1    0.64, 0.34‐1.2     1.1, 0.63‐1.9    0.77, 0.40‐1.5    0.95, 0.53‐1.7   1.0, 0.41‐2.6
   *P* value                               .75               .12               .18                .79              .45               .86              .93
   PS, 1 or 2 vs 0                                                                                                                                    
   OR, 95%CI                               0.90, 0.53‐1.5    0.60, 0.36‐1.0    0.92, 0.53‐1.6     0.92, 0.57‐1.5   1.8, 1.0‐3.1      1.1, 0.63‐1.8    2.0, 0.90‐4.3
   *P* value                               .69               .057              .78                .75              .040              .84              .088
   Peritoneal dissemination, yes vs no                                                                                                                
   OR, 95%CI                               0.97, 0.53‐1.8    1.1, 0.62‐1.9     1.1, 0.58‐2.1      1.3, 0.74‐2.3    0.80, 0.40‐1.6    1.3, 0.75‐2.4    1.4, 0.56‐3.5
   *P* value                               .92               .75               .78                .36              .52               .32              .47
  S‐1 plus cisplatin                                                                                                                                  
   Sex, female vs male                                                                                                                                
   OR, 95%CI                               0.98, 0.60‐1.6    0.66, 0.40‐1.1    0.52, 0.31‐0.88    1.4, 0.86‐2.3    2.8, 1.7‐4.9      1.5, 0.87‐2.4    1.9, 1.1‐3.4
   *P* value                               .94               .11               .014               .17              .0001             .15              .022
   CCr, 70 mL/min ≤ vs 70 mL/min \>                                                                                                                   
   OR, 95%CI                               0.59, 0.36‐0.99   0.60, 0.35‐1.0    0.78, 0.47‐1.3     0.74, 0.44‐1.2   0.55, 0.31‐0.98   0.91, 0.54‐1.6   0.94, 0.52‐1.7
   *P* value                               .044              .06               .35                .25              .042              .74              .84
   BMI, median ≤ vs median \> per gender                                                                                                              
   OR, 95%CI                               0.67, 0.42‐1.1    0.53, 0.33‐0.85   0.83, 0.52‐1.3     1.2, 0.76‐1.9    0.85, 0.49‐1.5    0.68, 0.42‐1.1   0.77, 0.44‐1.3
   *P* value                               .086              .0084             .43                .44              .55               .12              .34
   Age, 70 ≤ vs 70 \>                                                                                                                                 
   OR, 95%CI                               1.3, 0.77‐2.2     0.98, 0.57‐1.7    1.9, 1.1‐3.2       0.84, 0.51‐1.4   1.1, 0.59‐1.9     1.2, 0.72‐2.1    1.8, 1.0‐3.2
   *P* value                               .33               .94               .016               .51              .85               .46              .045
   PS, 1 or 2 vs 0                                                                                                                                    
   OR, 95%CI                               1.0, 0.60‐1.6     1.5, 0.87‐2.4     0.89, 0.54‐1.5     1.1, 0.67‐1.8    1.1, 0.60‐1.9     1.4, 0.84‐2.3    1.3, 0.74‐2.3
   *P* value                               .91               .15               .64                .71              .86               .20              .36
   Peritoneal dissemination, yes vs no                                                                                                                
   OR, 95%CI                               1.6, 0.91‐2.8     0.93, 0.53‐1.7    1.0, 0.59‐1.8      1.5, 0.85‐2.6    1.2, 0.65‐2.3     0.76, 0.42‐1.4   0.82, 0.41‐1.6
   *P* value                               .11               .81               .91                .16              .54               .38              .56

The median BMI of female patients treated with S‐1 plus oxaliplatin or S‐1 plus cisplatin were 20.4 kg/m^2^, and the BMI of males were 21.6 kg/m^2^.

Abbreviations: BMI, body mass index; CCr, creatinine clearance; CI, confidence interval; OR, odds ratio; PS performance status.
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The incidences of nausea and vomiting were higher in women, even though aprepitant was not commonly administered to patients treated with SOX. Aprepitant was given to 9.3% of male patients and 11.1% of female patients in the SOX group, and 74.5% of male patients and 73.9% of female patients in the CS group. Despite aprepitant administration, all grades of vomiting were still observed. Although the incidence of vomiting decreased to 22% (2/9) for women and 17% (4/24) for men, there was no difference in the incidence of vomiting between women and men (*P *=* *1.0). The incidence of vomiting (39%; 28/72) in women was significantly higher than that in men (18%; 41/233) (*P = *.0003) in the SOX group when aprepitant was not given (Table [4](#cas14117-tbl-0004){ref-type="table"}). The mean relative dose intensities (RDIs) for S‐1 during the three cycles of SOX were significantly lower in women (75.4%) than that in men (81.4%) (*P = *.032), while the RDIs for S‐1 during the two cycles of CS were 84.0% in women and 79.6% in men (*P = *.081) (Table [5](#cas14117-tbl-0005){ref-type="table"}). The reasons for the dose reduction of oxaliplatin did not differ between female patients or male patients treated with SOX (Table [6](#cas14117-tbl-0006){ref-type="table"}).

###### 

The incidence of any grade of nausea and vomiting by S‐1 plus oxaliplatin (SOX) and S‐1 plus cisplatin (CS)

  Arm        Aprepitant (1st cycle)   Female   Male   Fisher           
  ---------- ------------------------ -------- ------ -------- ------- -------
  Nausea                                                               
  SOX        No                       41       57     94       40      .015
  Yes        5                        56       9      38       .44     
  CS         No                       14       58     32       52      .64
  Yes        41                       60       91     50       .20     
  Vomiting                                                             
  SOX        No                       28       39     41       18      .0003
  Yes        2                        22       4      17       1.0     
  CS         No                       13       54     15       24      .011
  Yes        25                       37       33     18       .0038   

John Wiley & Sons, Ltd

###### 

Total dose and relative dose intensity

                          SOX         *P*              CS             *P*                                                                            
  ----------------------- ----------- ---------------- -------------- --------------------------------------------- --------------- ---------------- ---------------------------------------------
  S‐1                                                                                                                                                
  RDI (%)                 Median      83.7             75.0           .029[a](#cas14117-note-0010){ref-type="fn"}   83.3            83.3             .411[a](#cas14117-note-0010){ref-type="fn"}
                          \[Range\]   \[17.0‐114.5\]   \[13.0‐100\]                                                 \[2.4‐112.9\]   \[11.9‐101.7\]    
                          Mean, SD    81.4, 20.6       75.4, 21.6     .032[b](#cas14117-note-0011){ref-type="fn"}   79.6, 22.7      84.0, 18.0       .081[b](#cas14117-note-0011){ref-type="fn"}
  Oxaliplatin/cisplatin                                                                                                                              
  RDI (%)                 Median      98.3             75.0           .077[a](#cas14117-note-0010){ref-type="fn"}   87.5            87.5             .958[a](#cas14117-note-0010){ref-type="fn"}
                          \[Range\]   \[0‐100\]        \[28.0‐100\]                                                 \[0‐134.6\]     \[0‐102.9\]       
                          Mean, SD    83.5, 20.0       79.1, 20.0     .100[b](#cas14117-note-0011){ref-type="fn"}   80.3, 30.2      82.1, 27.2       .636[b](#cas14117-note-0011){ref-type="fn"}

SOX for 3 cycles, CS for 2 cycles.

Abbreviations: CS; S‐1 plus cisplatin, RDI, relative dose intensity; SD, standard deviation; SOX, S‐1 plus oxaliplatin.

Wilcoxon rank sum test.

*t*‐test.
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###### 

Reasons for dose reduction of oxaliplatin in S‐1 plus oxaliplatin (SOX)

  Dose reduction of oxaliplatin[a](#cas14117-note-0012){ref-type="fn"}                            Male   Female        
  ----------------------------------------------------------------------------------------------- ------ -------- ---- ------
  Thrombocytopenia: ≥75 000/mm^3^ (≤Grade 1) is not met by day 29                                 40     15.6     12   14.8
  Thrombocytopenia: \<25 000/mm^3^ (Grade 4)                                                      2      0.8      0    0
  Thrombocytopenia: platelet transfusion was performed                                            1      0.4      0    0
  Neutropenia: \<500/mm^3^ (Grade 4)                                                              1      0.4      1    1.2
  Febrile neutropenia: neutrophil count \< 1000/mm^3^ and fever (axillary temperature) ≥ 38.0°C   0      0        1    1.2
  Diarrhea: ≥Grade 3                                                                              10     3.9      4    4.9
  Stomatitis: ≥Grade 3                                                                            1      0.4      0    0
  Sensory neuropathy (Grade 2)                                                                    33     12.8     7    8.6
  Investigator\'s judgment                                                                        59     23.0     23   28.4

Patients can be included in more than one category.

John Wiley & Sons, Ltd

3.2. Efficacy {#cas14117-sec-0007}
-------------

In female patients, the median OS was 14.4 mo for SOX and 12.6 mo for CS (HR 0.812, 95% CI 0.577‐1.143; *P = *.233) (Figure [1](#cas14117-fig-0001){ref-type="fig"}), while the median PFS was 5.5 mo for SOX and 4.1 mo for CS (HR 0.877, 95% CI 0.621‐1.237; *P = *.454) (Figure [2](#cas14117-fig-0002){ref-type="fig"}). In the male patients, the median OS was 14.3 mo for SOX and 14.2 mo for CS (HR 0.976, 95% CI 0.800‐1.190; *P = *.808) (Figure [1](#cas14117-fig-0001){ref-type="fig"}), while median PFS was 5.4 mo for SOX and 5.5 mo for CS (HR 0.952, 95% CI 0.778‐1.165; *P = *.633) (Figure [2](#cas14117-fig-0002){ref-type="fig"}). The response rates were 49.4% (95% CI 38.1‐60.7) in female patients and 54.8% (95% CI 48.4‐61.0) in male patients for SOX (*P = *.443), and 46.7% (95% CI 36.1‐57.5) in female patients and 52.9% (95% CI 46.4‐59.4) in male patients for CS (*P = *.325). No significant differences in efficacy with regard to OS, PFS, and response rate were identified between the sexes in either treatment group.

![Overall survival (OS) according to sex and treatment arms. Checkmarks represent censored patients. CS, S‐1 plus cisplatin; FAS, full analysis set; SOX, S‐1 plus oxaliplatin.](CAS-110-2875-g001){#cas14117-fig-0001}

![Progression‐free survival according to sex and treatment arms. Checkmarks represent censored patients. CS, S‐1 plus cisplatin; FAS, full analysis set; SOX, S‐1 plus oxaliplatin.](CAS-110-2875-g002){#cas14117-fig-0002}

4. DISCUSSION {#cas14117-sec-0008}
=============

Leukopenia, neutropenia, nausea, and vomiting during the 1st cycle of SOX treatment, and vomiting and stomatitis during the 1st cycle of CS treatment were more frequently observed in female patients compared with male patients. In contrast, thrombocytopenia developed more often in male patients compared with female patients. However, no significant sex‐related difference was observed in the incidence of subjective adverse reactions such as diarrhea because patients could themselves temporarily stop oral S‐1 by assessing adequate self‐administration, in contrast with infused 5‐FU. There was also no difference in the incidence of leukopenia and neutropenia in patients treated with CS. The pharmacokinetics of 5‐FU after oral S‐1 administration could vary in patients because cisplatin can impair renal function and decrease 5‐FU clearance. This decrease is through reduced clearance of gimeracil, a DPD inhibitor, that leads to high concentrations of 5‐FU in the blood. Therefore, the effect of cisplatin treatment on sex‐related differences in adverse reactions induced by 5‐FU would be more variable compared with oxaliplatin treatment. Despite the observed differences between female patients and male patients of these toxicities, their cause was not clearly explained from this study on its own.

5‐Fluorouracil clearance is significantly lower in women than in men regardless of patient age and the given 5‐FU dose.[2](#cas14117-bib-0002){ref-type="ref"} Plasma samples from the 1st cycle of 391 female patients and 536 male patients treated with a 2400 mg/m^2^ continuous infusion of 5‐FU over 44‐48 h were tested for 5‐FU. These analyses indicated that, when comparing the proposed optimal area under the plasma drug concentration‐time curve (AUC) target range of 20‐30 mg h/L, women received supraoptimal doses compared with men (*P *=* *.0083).[16](#cas14117-bib-0016){ref-type="ref"} This higher plasma 5‐FU concentration was significantly related to severer neutropenia and stomatitis.[17](#cas14117-bib-0017){ref-type="ref"} More than 80% of a given dose of 5‐FU is rapidly catabolized to dihydrofluorouracil by DPD, the rate‐limiting enzyme of pyrimidine metabolism, and to inactive dihydrouracil.[7](#cas14117-bib-0007){ref-type="ref"} Toxicity from 5‐FU in women was found in a recent study to be independent of *DPYD* genotype. Female patients had a two‐fold higher risk for severe 5‐FU‐related toxicity compared with male patients and toxicity in women was independent of *DPYD* genotype because the OR for toxicity of 41.8 (95% CI, 9.2‐190, *P *\<* *.0001) in men with *DPYD* polymorphism was much higher than the OR of 1.33 (95% CI, 0.34‐5.2, *P *=* *.68) in women. In addition, analysis from the same study of DPD expression and activity in the human liver did not reveal any sex‐related differences. Evidence for methylation of the *DPYD* promotor in the same DNA from the same human liver was not found.[5](#cas14117-bib-0005){ref-type="ref"} Pretherapeutic dihydrouracil concentration was significantly higher in female colorectal cancer patients compared with male patients, however the dihydrouracil/uracil ratio did not differ according to sex. A high level of uracil in females might therefore be associated with hematologic toxicity after 5‐FU‐based chemotherapy.

Another recent study has shown that global capecitabine toxicities were associated with rare, functional *DPYD* alleles 2846T\>A (minor allele frequency, 0.6%) and \*2A (IVS14 + 1G\>A, 0.4%) (combined OR, 5.51; *P *=* *.0013), the common *TYMS* polymorphism 5′VNTR2R/3R (47%), and a 3′UTR 6‐bp Indel (31%) (combined OR, 1.31; *P *=* *9.4 × 10^−6^).[8](#cas14117-bib-0008){ref-type="ref"} The higher incidence of 5‐FU‐related toxicities is difficult to explain by these rare *DPYD* variants. In total, 3‐5% of Caucasians have reduced DPD activity,[18](#cas14117-bib-0018){ref-type="ref"} however *DPYD* variants in the Japanese population are somewhat different from the previously reported Caucasian variants. *DPYD* alleles 2303C\>A and 103G\>T might play important roles in 5‐FU‐related toxicity for Japanese patients.[19](#cas14117-bib-0019){ref-type="ref"} The sensitivity of *DPYD* genetic testing depends on the number of variants investigated. By combining the *DPYD* variants c.1905 + 1G\>A (also known as *DPYD *\* 2A, IVS14 + 1G\>A), c.2846A\>T, c.1679T\>G, c.1129‐5923C\>G, the 20%‐30% rate of early‐onset 5‐fluorouracil toxicities can be explained.[20](#cas14117-bib-0020){ref-type="ref"}, [21](#cas14117-bib-0021){ref-type="ref"} Patients without a *DPYD* decreased/no function variant may still experience severe toxicity due to other genetic, environmental, or other factors.[21](#cas14117-bib-0021){ref-type="ref"}

Tegafur is converted to 5‐FU mainly by CYP2A6, and polymorphisms in CYP2A6 are thought to be related to 5‐FU toxicity.[22](#cas14117-bib-0022){ref-type="ref"} In addition, previous studies have suggested that CYP2A6 activity is higher in women and could be induced by estradiol via ERα, although further studies are required to confirm this suggestion.[23](#cas14117-bib-0023){ref-type="ref"} Sex differences are well known in disease manifestations and treatment effects such as in autoimmune or cardiovascular diseases, and reaction to vaccines. Despite these insights, the X chromosome is scrutinized less often in the current era of population genetics analyses due to unique statistical challenges,[24](#cas14117-bib-0024){ref-type="ref"} although genome analyses of sex chromosomes could resolve some profound medical questions such as described here. The reason for the higher incidence of thrombocytopenia in male patients treated with CS therapy could not be clearly understood. Thrombocytopenia after CS was not correlated with body mass index, this result differed from that of a previous study on cisplatin‐based therapy.[11](#cas14117-bib-0011){ref-type="ref"}

In our study, no statistically significant relationship between treatment effects and sex was observed, although the incidence of adverse events was higher in female patients who more commonly have undifferentiated type adenocarcinoma with a worse prognosis compared with the differentiated type. Intensive antiemetic therapy with aprepitant should be considered because of the higher incidence of nausea and vomiting in SOX and vomiting in CS. It is difficult to reduce the starting dose of SOX for female patients due to their higher incidence of adverse events compared with male patients and because severe toxicities were rarely induced by SOX with 100 mg/m^2^ of oxaliplatin.[15](#cas14117-bib-0015){ref-type="ref"} Conversely, the oxaliplatin dose should rather be increased to the recommended dose of 130 mg/m^2^, as proposed by the phase I/II trial on SOX,[25](#cas14117-bib-0025){ref-type="ref"} along with full supportive antiemetic therapy for male patients. In conclusion, incidences of sex‐related differences in adverse reactions during treatment with SOX and CS were confirmed in the G‐SOX study. Further fundamental research studies are warranted to pursue the underlying cause.
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